| 107379-0 | PT Whole body Views |
| 107382-4 | PET+CT Whole body Views |
| 107439-2 | XR Whole body Views |
| 108347-6 | XR.slot radiography Whole body Views |
| 39622-6 | SPECT Guidance for abscess localization of Whole body |
| 39623-4 | NM Guidance for abscess localization of Whole body |
| 39669-7 | NM Whole body Views W Tc-99m Arcitumomab IV |
| 39675-4 | SPECT Whole body for infection W Ga-67 IV |
| 39678-8 | SPECT Whole body for tumor W Ga-67 IV |
| 39680-4 | SPECT Whole body W Ga-67 IV |
| 39683-8 | NM Whole body Views W Ga-67 IV |
| 39686-1 | NM Whole body Views for lymphoma W Ga-67 IV |
| 39698-6 | NM Whole body Views W I-131 MIBG IV |
| 39748-9 | SPECT Whole body for tumor W Tc-99m Sestamibi IV |
| 39749-7 | NM Whole body Views for tumor W Tc-99m Sestamibi IV |
| 39762-0 | SPECT Guidance for localization of tumor of Whole body |
| 39763-8 | NM Guidance for localization of tumor of Whole body |
| 39827-1 | NM Whole body Views for endocrine tumor W I-131 MIBG IV |
| 39828-9 | NM Whole body Views for endocrine tumor W In-111 pentetreotide IV |
| 39829-7 | NM Whole body Views for tumor W Ga-67 IV |
| 39830-5 | NM Whole body Views for infection W Ga-67 IV |
| 39839-6 | SPECT Whole body W I-131 MIBG IV |
| 39840-4 | NM Whole body Delayed Views W I-131 MIBG IV |
| 39842-0 | NM Whole body Delayed Views W In-111 Satumomab IV |
| 39844-6 | SPECT Whole body W In-111 Satumomab IV |
| 39845-3 | NM Whole body Views W In-111 Satumomab IV |
| 39875-0 | NM Whole body Delayed Views W Ga-67 IV |
| 41837-6 | SPECT Whole body W Tc-99m Arcitumomab IV |
| 42170-1 | NM Whole body Views for lymphoma |
| 42171-9 | NM Whole body Views for tumor |
| 42175-0 | NM Whole body Views |
| 42292-3 | SPECT Whole body for tumor W Tl-201 IV |
| 42305-3 | NM Whole body Views for tumor W Tl-201 IV |
| 42708-8 | NM Whole body Views W In-111 tiuxetan IV |
| 42711-2 | NM Whole body Views W In-111 tagged WBC IV |
| 44139-4 | PT Whole body |
| 46297-8 | SPECT Whole body |
| 46305-9 | CT Whole body |
| 46306-7 | CT Whole body W contrast IV |
| 46358-8 | MR Whole body |
| 69237-6 | SPECT Whole body for tumor |
| 80499-7 | MR Whole body WO and W contrast IV |
| 81547-2 | SPECT Whole body W In-111 pentetreotide IV |
| 81555-5 | PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV |
| 81560-5 | SPECT Whole body W In-111 capromab pendetide IV |
| 81583-7 | NM Whole body Views W Sm-153 IV |
| 81584-5 | NM Whole body Views W tagged WBC IV |
| 81586-0 | NM Whole body Views W Y-90 ibritumomab tiuxetan IV |
| 81588-6 | NM Whole body Views for thyroid tumor |
| 81589-4 | NM Whole body Views for infection or inflammation |
| 81598-5 | NM Whole body Views for thyroid tumor metastasis post therapy |
| 81599-3 | NM Guidance for multiple days for localization of tumor of Whole body |
| 82136-3 | NM Whole body Views for tumor W I-123 MIBG IV |
| 82805-3 | PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV and WO contrast |
| 82806-1 | PET+CT Guidance for localization of tumor of Whole body-- W 18F-FDG IV and W contrast IV |
| 8284-2 | Whole body Maximum circumference |
| 89631-6 | SPECT+CT Guidance for localization of tumor of Whole body |
| 89842-9 | SPECT+CT Whole body |